Eighteen-year analysis of anaesthetic management in Brugada syndrome: The BRUGANAES study
Authors' conclusion
Most of the patients undergoing anaesthesia for an interventional procedure received an anaesthetic drug classified as not recommended.
Study context
- Population
- Brugada syndrome (BrS) patients undergoing any type of anaesthesia intervention, tertiary hospital in Barcelona, 1 January 2006 to 31 December 2023
- Participants
- 111 patients · 189 procedures
- Outcome
- Malignant ventricular arrhythmias and/or sudden cardiac death (SCD) during and up to 30 days postanaesthesia
- Follow-up
- Up to 30 days
Methodological detailsobservational, single-centre (tertiary hospital)
- Observational
- Single-centre (tertiary hospital)
Main finding
As reported in the abstract
Malignant ventricular arrhythmias and/or SCD · intraoperatively
Primary outcome occurred in 2 patients intraoperatively (% of procedures)
1%
Bradycardia-induced ventricular fibrillation after a nonrecommended drug
1
Transient ventricular tachycardia after a drug not listed as potentially harmful
1
Observational data: associations, not effects.
Secondary outcomes
Anaesthesia type and drug use
- GA (% of cases)
- 51.3%
- Sedation (% of cases)
- 36%
- Regional/neuraxial anaesthesia exclusively (% of cases)
- 12.7%
- Nonrecommended drugs (propofol, ketamine, local anaesthetics) used, procedures
- 129 (68.3%)
- Epidural blocks (% of regional anaesthesia cases), mostly obstetrics
- 34%
- Subarachnoid blocks (% of regional anaesthesia cases)
- 31.8%
Original publication
Eighteen-year analysis of anaesthetic management in Brugada syndrome: The BRUGANAES study. Eur J Anaesthesiol. Published 12 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →